Royalty Pharma plc (RPRX) NASDAQ
49.49
-0.05(-0.10%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
49.49
-0.05(-0.10%)
Currency In USD
Address
110 East 59th Street
New York City, NY 10022
United States of America (the)
Phone
212 883 0200
Sector
Healthcare
Industry
Biotechnology
Employees
75
First IPO Date
June 16, 2020
| Name | Title | Pay | Year Born |
| Pablo Legorreta | Founder, Chairman of the Board & Chief Executive Officer | 44.02M | 1963 |
| Marshall Urist | Executive Vice President of Research & Investments | 1.32M | 1977 |
| Christopher Hite | Chairman of Partnering & Investments | 1.32M | 1968 |
| Terrance Coyne | Executive Vice President & Chief Financial Officer | 1.32M | N/A |
| James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer | 3.4M | 1971 |
| Arthur Richard McGivern | Executive VP & Chief Legal Officer | 0 | 1975 |
| Ashwin Pai | Executive Vice President of Investments & Partnering | 0 | N/A |
| Sandy Balkin | Senior Vice President of Strategy & Analytics | 0 | N/A |
| Scott Raichilson | Chief Accounting Officer | 0 | N/A |
| Sara Klymkowsky | Senior Vice President of Research & Investments | 0 | N/A |
| Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer | 0 | N/A |
| George Grofik | Senior Vice President and Head of Investor Relations & Communications | 0 | N/A |
| Sean Weisberg | Vice President of Capital Markets & Deputy General Counsel | 0 | N/A |
| Brienne Kugler | Senior Vice President of Research & Investments | 0 | N/A |
| Kristin Stafford | Senior Vice President & Chief Accounting Officer | 0 | 1983 |
| Molly Sawaya | Executive Vice President & Head of Human Capital | 0 | N/A |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.